Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 491Rectal Neoplasms 267Colonic Neoplasms 218Pancreatic Neoplasms 186Stomach Neoplasms 181Esophageal Neoplasms 134Breast Neoplasms 118Neoplasm Metastasis 116Squamous Cell Carcinoma of Head and Neck 94Head and Neck Neoplasms 92Neoplasms 88Adenocarcinoma Of Esophagus 67Esophageal Squamous Cell Carcinoma 61Carcinoma, Hepatocellular 54Adenocarcinoma 40Nasopharyngeal Carcinoma 33Cholangiocarcinoma 32Biliary Tract Neoplasms 26Anus Neoplasms 26Gastrointestinal Neoplasms 25Carcinoma, Squamous Cell 25Carcinoma, Non-Small-Cell Lung 25Keratosis, Actinic 22Gallbladder Neoplasms 21Urinary Bladder Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 20Liver Neoplasms 20Bile Duct Neoplasms 19Ovarian Neoplasms 16Carcinoma 16

Interventions

Oxaliplatin 2Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1Surgical Procedures, Operative 1S 1 (combination) 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Borderline Resectable Pancreatic Cancer × Fluorouracil × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡